300K settlement follows unlawful prescribing claims
The federal settlement resolves allegations of unlawful controlled substance prescribing and absent patient records and restricts future DEA registration for certain controlled substances.
By
Kathryn Wighton
October 1, 2026
Clinical Scorecard: 300K settlement follows unlawful prescribing claims
At a Glance
Category Detail
Condition Unlawful prescribing of controlled substances Key Mechanisms Failure to maintain patient records and proper prescribing practices under the Controlled Substances Act Target Population Patients receiving controlled substances prescriptions Care Setting Gastroenterology practice
Key Highlights
Settlement of $300,000 reached over unlawful prescribing allegations Involved at least 127 controlled substance prescriptions Prescriptions included opioids and benzodiazepines without proper recordkeeping Voluntary surrender of DEA registration on April 22, 2026 Agreement to complete continuing medical education and undergo additional DEA monitoring Guideline-Based Recommendations
Diagnosis
Management
Maintain accurate inventorying, tracking, and recordkeeping for controlled substances Monitoring & Follow-up
Undergo additional DEA monitoring as part of settlement agreement Risks
Potential for diversion of controlled substances due to inadequate recordkeeping Patient & Prescribing Data
Patients prescribed controlled substances by the gastroenterologist
Prescribing practices must comply with the Controlled Substances Act
Clinical Best Practices
Ensure compliance with recordkeeping requirements for controlled substances Engage in continuing medical education regarding controlled substance prescribing Related Resources & Content
